Skip to main content

Table 1 Demographic and clinical parameters at study inclusion

From: Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial

Category

All n = 40

SOC n = 20

TPE n = 20

p

Age—years

56 (47–63)

57 (46–65)

55 (48–60)

0.663

Sex—no (%)

   

0.429

Male

32 (80)

17 (85)

15 (75)

 

Female

8 (20)

3 (15)

5 (25)

 

BMI—kg/m2

25.4 (22.6–32.3)

25.5 (24.1–35.4)

25.1 (20.2–31.1)

0.114

Comorbidities—no (%)

Obesity

12 (30)

6 (30)

6 (30)

1

Hypertension

17 (42.5)

9 (45)

8 (40)

0.749

Diabetes

6 (15)

5 (25)

1 (5)

0.077

COPD

4 (10)

3 (15)

1 (5)

0.292

CHF

7 (17.5)

4 (20)

3 (15)

0.677

CAD

4 (10)

2 (10)

2 (10)

1

CKD

7 (17.5)

4 (20)

3 (15)

0.677

Immunosuppression

8 (20)

3 (15)

5 (25)

0.429

SOT or HSCT

5 (12.5)

3 (15)

2 (10)

0.633

Sepsis onset—no (%)

Ambulatory

26 (65)

13 (65)

13 (65)

1

Hospital

14 (35)

7 (35)

7 (35)

1

Side of infection—no (%)

Pulmo

25 (62.5)

12 (60)

13 (65)

0.744

Abdomen

12 (30)

6 (30)

6 (30)

1

Soft tissue

2 (5)

2 (10)

0 (0)

0.147

Endocarditis

1 (2.5)

0 (0)

1 (5)

0.311

Identified pathogen—no (%)

Gram + 

12 (30)

6 (30)

6 (30)

1

Gram-

12 (30)

5 (25)

7 (35)

0.49

Fungi

2 (5)

1 (5)

1 (5)

1

Viral

3 (7.5)

2 (10)

1 (5)

0.548

Mixed

2 (5)

2 (10)

0 (0)

0.147

Non-identified

9 (22.5)

4 (20)

5 (25)

0.705

SOFA score (points)

16.5 (14–19)

18 (14–20)

16 (13–18)

0.125

Norepinephrine dose (μg/kg/min)

0.591 (0.468–0.84)

0.582 (0.458–0.84)

0.598 (0.549–0.867)

0.724

VIS (points)

61 (48–85)

61 (46–85)

60 (55–87)

0.98

Mechanical ventilation—no (%)

37 (92.5)

18 (90)

19 (95)

0.548

Oxygenierungsindex (PaO2/FiO2)

145 (97–243)

156 (81–221)

132 (98–278)

0.624

ECMO—no (%)

vv-ECMO

9 (22.5)

4 (20)

5 (25)

0.705

va-ECMO

2 (5)

2 (10)

0 (0)

0.147

Renal replacement therapy—no (%)

26 (65)

14 (70)

12 (60)

0.507

Lactate—mmol/l

4 (2.6–6.1)

4.4 (2.6–6.9)

4 (2.6–5.9)

0.513

Organ failure—no (%)

Respiratory

39 (97.5)

19 (95)

20 (100)

0.311

Coagulation

19 (47.5)

10 (50)

9 (45)

0.752

Liver

16 (40)

11 (55)

5 (25)

0.053

Cardiovascular

40 (100)

20 (100)

20 (100)

1

Neurological

39 (97.5)

20 (100)

19 (95)

0.311

Renal

32 (80)

16 (80)

16 (80)

1

CRP (mg/l)

297 (168–350)

279 (115–410)

297 (213–350)

0.698

PCT (μg/l)

30 (7–82)

36 (13–101)

20 (6–59)

0.159

WBC (103/μl)

17 (8–20)

12 (5–18)

18 (10–23)

0.244

  1. Shown are both demographic and clinical characteristics at randomization for patients receiving standard of care treatment (SOC) as well as patients receiving additive therapeutic plasma exchange (TPE)
  2. BMI body mass index, CAD coronary artery disease, CHF congestive heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, ECMO extracorporeal membrane oxygenation (vv venovenous, va venoarterial), HSCT hematopoietic stem cell transplant, NE norepinephrine, PCT procalcitonine, RRT renal replacement therapy, SOFA Sequential Organ Failure Assessment, SOT solid organ transplant, VIS vasoactive-inotropic score, WBC white blood cell count